BIOMAT Database Logo BIOMAT Database Logo

Substituted analogues of GV150526 as potent glycine binding site antagonists in animal models of cerebral ischemia. 1999

R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
Medicines Research Centre, Glaxo Wellcome S.p.A., Via Fleming 4, 37100 Verona, Italy. rdf26781@Glaxo.Wellcome.co.uk

A series of analogues of the indole-2-carboxylate GV150526, currently in clinical trials as a potential neuroprotective agent for the control of the cerebral damage after stroke onset, was designed based on previous studies dealing with the electronic features of the north-east region of the glycine binding site associated with the NMDA receptor. In particular, the substitution of the para position of the terminal phenyl ring of GV150526 with suitable hydrophilic groups resulted in the identification of a new class of glycine antagonists. These compounds exhibited nanomolar in vitro affinity to the glycine binding site, high receptor selectivity, and outstanding in vivo potency. In particular, 3-[(E)-2-[(4-ureidomethylphenyl)aminocarbonyl]ethenyl]-4, 6-dichloroindole-2-carboxylic acid was found to be highly effective in the middle cerebral artery occlusion (MCAo) model in the rat, an animal model of focal ischemia, when given both prior to and after the occlusion of the middle cerebral artery. Notably, a significant neuroprotective effect was seen in this model postischaemia, when the administration of this compound was delayed up to 6 h from the occlusion of the middle cerebral artery, further confirming the wide therapeutic window seen for GV150526A.

UI MeSH Term Description Entries
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002264 Carboxylic Acids Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. Carboxylic Acid,Acid, Carboxylic,Acids, Carboxylic
D002544 Cerebral Infarction The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction). Anterior Choroidal Artery Infarction,Cerebral Infarct,Infarction, Cerebral,Posterior Choroidal Artery Infarction,Subcortical Infarction,Cerebral Infarction, Left Hemisphere,Cerebral Infarction, Right Hemisphere,Cerebral, Left Hemisphere, Infarction,Cerebral, Right Hemisphere, Infarction,Infarction, Cerebral, Left Hemisphere,Infarction, Cerebral, Right Hemisphere,Infarction, Left Hemisphere, Cerebral,Infarction, Right Hemisphere, Cerebral,Left Hemisphere, Cerebral Infarction,Left Hemisphere, Infarction, Cerebral,Right Hemisphere, Cerebral Infarction,Right Hemisphere, Infarction, Cerebral,Cerebral Infarctions,Cerebral Infarcts,Infarct, Cerebral,Infarction, Subcortical,Infarctions, Cerebral,Infarctions, Subcortical,Infarcts, Cerebral,Subcortical Infarctions
D002545 Brain Ischemia Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION. Cerebral Ischemia,Ischemic Encephalopathy,Encephalopathy, Ischemic,Ischemia, Cerebral,Brain Ischemias,Cerebral Ischemias,Ischemia, Brain,Ischemias, Cerebral,Ischemic Encephalopathies
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005998 Glycine A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. Aminoacetic Acid,Glycine, Monopotassium Salt,Glycine Carbonate (1:1), Monosodium Salt,Glycine Carbonate (2:1), Monolithium Salt,Glycine Carbonate (2:1), Monopotassium Salt,Glycine Carbonate (2:1), Monosodium Salt,Glycine Hydrochloride,Glycine Hydrochloride (2:1),Glycine Phosphate,Glycine Phosphate (1:1),Glycine Sulfate (3:1),Glycine, Calcium Salt,Glycine, Calcium Salt (2:1),Glycine, Cobalt Salt,Glycine, Copper Salt,Glycine, Monoammonium Salt,Glycine, Monosodium Salt,Glycine, Sodium Hydrogen Carbonate,Acid, Aminoacetic,Calcium Salt Glycine,Cobalt Salt Glycine,Copper Salt Glycine,Hydrochloride, Glycine,Monoammonium Salt Glycine,Monopotassium Salt Glycine,Monosodium Salt Glycine,Phosphate, Glycine,Salt Glycine, Monoammonium,Salt Glycine, Monopotassium,Salt Glycine, Monosodium
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000927 Anticonvulsants Drugs used to prevent SEIZURES or reduce their severity. Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining

Related Publications

R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists.
March 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,
R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
Substituted N-(3,5-dichlorobenzenesulfonyl)-L-prolyl-phenylalanine analogues as potent VLA-4 antagonists.
February 2002, Bioorganic & medicinal chemistry letters,
R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
[Animal models of cerebral ischemia].
September 1983, [Hokkaido igaku zasshi] The Hokkaido journal of medical science,
R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
Enantiomerically pure tetrahydroquinoline derivatives as in vivo potent antagonists of the glycine binding site associated to the NMDA receptor.
November 2003, Bioorganic & medicinal chemistry letters,
R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
[Experimental animal models in cerebral ischemia].
November 1998, Neurologia (Barcelona, Spain),
R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
Substituted dipiperidine alcohols as potent CCR2 antagonists.
June 2008, Bioorganic & medicinal chemistry letters,
R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
Phenyl-substituted analogues of oxotremorine as muscarinic antagonists.
January 1992, Journal of medicinal chemistry,
R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
Animal models of cerebral ischemia: A review.
November 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
Diaryl substituted pyrazoles as potent CCR2 receptor antagonists.
February 2007, Bioorganic & medicinal chemistry letters,
R Di Fabio, and N Conti, and E De Magistris, and A Feriani, and S Provera, and F M Sabbatini, and A Reggiani, and L Rovatti, and R J Barnaby
Substituted benzamides as cerebral dopamine antagonists in rodents.
May 1977, Neuropharmacology,
Copied contents to your clipboard!